Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Animals (3)
- Female (3)
- Humans (3)
- Pregnancy (3)
- Adenosine Diphosphate (1)
-
- Alginates (1)
- Antihypertensive Agents (1)
- Benzylamines (1)
- Cell Line (1)
- DNA (1)
- Drug Administration Routes (1)
- Drug Carriers (1)
- Drug Design (1)
- Drug Evaluation (1)
- Drug Evaluation, Preclinical (1)
- Endothelium (1)
- Endothelium, Vascular (1)
- Fetal Diseases (1)
- Genetic Predisposition to Disease (1)
- Genome (1)
- Genome, Human (1)
- Glucuronic Acid (1)
- Hexuronic Acids (1)
- Human (1)
- Immune System (1)
- Macaca mulatta (1)
- Male (1)
- Mice (1)
- Microspheres (1)
- Oxidative Stress (1)
Articles 1 - 11 of 11
Full-Text Articles in Medicine and Health Sciences
Development And Characterization Of An Indoleamine 2,3-Dioxygenase (Ido) Deficient Mouse Model Of Preeclampsia, Mark Santillan, Christopher Pelham, Pimonrat Ketsawatsomkron, Donna Santillan, Baoli Yang, Stephen Hunter, Curt Sigmund
Development And Characterization Of An Indoleamine 2,3-Dioxygenase (Ido) Deficient Mouse Model Of Preeclampsia, Mark Santillan, Christopher Pelham, Pimonrat Ketsawatsomkron, Donna Santillan, Baoli Yang, Stephen Hunter, Curt Sigmund
Mark K. Santillan
No abstract provided.
Single Umbilical Artery: Does Side Matter?., Mark Santillan, Donna Santillan, Diedre Fleener, Barbara Stegmann, Gideon Zamba, Stephen Hunter, Jerome Yankowitz
Single Umbilical Artery: Does Side Matter?., Mark Santillan, Donna Santillan, Diedre Fleener, Barbara Stegmann, Gideon Zamba, Stephen Hunter, Jerome Yankowitz
Mark K. Santillan
INTRODUCTION: The aim of this study was to determine if laterality of an absent umbilical artery (AUA) is associated with specific sonographic findings, chromosomal defects or postpartum birth defects.
MATERIALS AND METHODS: In this retrospective cohort study, ultrasound reports and medical records of patients who received an obstetric ultrasound at the University of Iowa Hospitals and Clinics with an identified laterality of the AUA from 1989 to 2007 (n = 405) were reviewed. Rates of sonographic abnormalities between fetuses with a right versus left AUA were compared using Fisher's exact test. Adjustments for confounding were made using logistic regression modeling. …
Indoleamine 2,3 Dioxygenase (Ido) Deficiency Results: In Vascular Dysfunction And Proteinuria In Pregnancy, Mark Santillan, Christopher Pelham, Pimonrat Ketsawatsomkron, Donna Santillan, Baoli Yang, Stephen Hunter, Curt Sigmund
Indoleamine 2,3 Dioxygenase (Ido) Deficiency Results: In Vascular Dysfunction And Proteinuria In Pregnancy, Mark Santillan, Christopher Pelham, Pimonrat Ketsawatsomkron, Donna Santillan, Baoli Yang, Stephen Hunter, Curt Sigmund
Mark K. Santillan
No abstract provided.
Maternal Demographic And Clinical Variables Do Not Predict Iuc Placement: Evidence For Postplacental Iuc Placement, J. Hansen, Mark Santillan, B. Stegmann, T. Foster, Abbey Hardy-Fairbanks
Maternal Demographic And Clinical Variables Do Not Predict Iuc Placement: Evidence For Postplacental Iuc Placement, J. Hansen, Mark Santillan, B. Stegmann, T. Foster, Abbey Hardy-Fairbanks
Mark K. Santillan
No abstract provided.
Cell Encapsulation As A Potential Nondietary Therapy For Maternal Phenylketonuria, Donna Santillan, Mark Santillan, Stephen Hunter
Cell Encapsulation As A Potential Nondietary Therapy For Maternal Phenylketonuria, Donna Santillan, Mark Santillan, Stephen Hunter
Mark K. Santillan
OBJECTIVE: The objective of this work was to determine whether cells overexpressing phenylalanine (Phe) hydroxylase (PAH) can significantly reduce Phe in vitro for potential use as a therapy for preventing maternal phenylketonuria. STUDY DESIGN: Human 293T and WRL68 cell lines were transiently and stably transfected to overexpress PAH. Cells were encapsulated within microspheres of sodium alginate. Timed measurements of Phe in media were performed using tandem mass spectrometry. RESULTS: Both nonencapsulated and encapsulated transiently transfected cells overexpressing PAH significantly reduced the Phe concentration in media by approximately 50% in comparison to mock-transfected cells. Cell line clones stably expressing PAH significantly …
Fetal Effects Of Drugs Commonly Used In Critical Care, Mark Santillan, J. Yankowitx
Fetal Effects Of Drugs Commonly Used In Critical Care, Mark Santillan, J. Yankowitx
Mark K. Santillan
No abstract provided.
The Effect Of A Novel Glycoprotein Iib/Iiia Antagonist, Sr 121566a, On Platelet Aggregation And Activation In Rhesus Monkeys., Mark Santillan, J. Herring, D. Hoppensteadt, W. Jeske, J. Herbert, J. Fareed
The Effect Of A Novel Glycoprotein Iib/Iiia Antagonist, Sr 121566a, On Platelet Aggregation And Activation In Rhesus Monkeys., Mark Santillan, J. Herring, D. Hoppensteadt, W. Jeske, J. Herbert, J. Fareed
Mark K. Santillan
SR 121566A represents a peptidomimetic glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor 3-[N- 4-[4-(aminoiminomethyl)phenyl]-1,3-thiazol-2-yl ) -N-(1-carboxymethylpiperid-4-yl) amino] propionic acid, trihydrochloride. To investigate the intravenous and subcutaneous pharmacodynamics of this agent, a primate model ( Macaca mulatta) was used. The IC50 for adenosine diphosphate (ADP) (10 micromol/L)-induced platelet aggregation in this primate platelet system was found to be 45 +/- 6 nmol/L. Comparatively in the human platelet rich plasma system, SR 121566A demonstrated an IC50 of 39 +/- 4 nmol/L. Graded doses of SR 121566A in the range of 25-400 microg/kg were administered intravenously. Blood samples were drawn from individual groups of primates …
Preeclampsia/Eclampsia: An Immediate And Long Term Problem, Mark Santillan, Stephen Hunter
Preeclampsia/Eclampsia: An Immediate And Long Term Problem, Mark Santillan, Stephen Hunter
Mark K. Santillan
No abstract provided.
From Molecules To Medicine: A Future Cure For Preeclampsia?, Mark Santillan, Donna Santillan, Curt Sigmund, Stephen Hunter
From Molecules To Medicine: A Future Cure For Preeclampsia?, Mark Santillan, Donna Santillan, Curt Sigmund, Stephen Hunter
Mark K. Santillan
In the United States, preeclampsia (PreE) affects 5-7% of all pregnancies, yet represents 15% of all maternal-fetal morbidity and mortality. PreE causes fetal growth restriction, oligohydramnios, fetal death, and maternal seizures, stroke, cerebrovascular hemorrhage and death. It has immediate and potentially long-term effects on both the fetus and mother. To date, the molecular pathogenesis of PreE is largely unknown. Multiple pathways, including dysfunctional angiogenesis, inappropriate placentation, oxidative stress and an altered immunological milieu have been proposed as key players in the development of PreE. In addition, genetic factors in all of these pathways are essential components in the etiology of …
Non-Invasive Fetal Genome Sequencing: Opportunities And Challenges., Holly Tabor, Jeffrey Murray, Hilary Gammill, Jacob Kitzman, Matthew Snyder, Mario Ventura, Alexandra Lewis, Ruolan Qiu, Lavone Simmons, Craig Rubens, Mark Santillan, Evan Eichler, Edith Cheng, Michael Bamshad, Jay Shendure
Non-Invasive Fetal Genome Sequencing: Opportunities And Challenges., Holly Tabor, Jeffrey Murray, Hilary Gammill, Jacob Kitzman, Matthew Snyder, Mario Ventura, Alexandra Lewis, Ruolan Qiu, Lavone Simmons, Craig Rubens, Mark Santillan, Evan Eichler, Edith Cheng, Michael Bamshad, Jay Shendure
Mark K. Santillan
No abstract provided.
New Cdc Group B Streptococcal (Gbs) Guidelines, Mark Santillan, Donna Santillan
New Cdc Group B Streptococcal (Gbs) Guidelines, Mark Santillan, Donna Santillan
Mark K. Santillan
No abstract provided.